Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07037433 · ClinicalTrials.gov registry record · Phase 3

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

A Phase 3 study of Obesity and Overweight, sponsored by Amgen.

Recruiting
Registry status
Phase 3
Development phase
12,800
Enrollment target
20
Study locations

NCT07037433 is a Phase 3 study of Obesity and Overweight that is actively recruiting participants, run by Amgen. The registered enrollment target is 12,800 participants, above the 807-participant average among 1,053 other Obesity trials with a reported enrollment target (1486% higher). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07037433, a Phase 3 study of Obesity and Overweight, is actively recruiting participants, sponsored by Amgen.

RECRUITING
Registry status
Phase 3
Development phase
12,800 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

Conditions Studied

Obesity Overweight Atherosclerotic Cardiovascular Disease

Interventions

  • DRUG Placebo
  • DRUG Maridebart Cafraglutide

Study Locations (20)

California

  • Valley Clinical Trials, LLC dba Flourish Research - Covina
  • Velocity Clinical Research- Huntington Park - Huntington Park
  • Velocity Clinical Research- Los Angeles - La Mesa
  • Orange County Research Center - Lake Forest
  • Biopharma Informatic - The Cardiovascular Center - Redding
  • Encompass Clinical Research - Spring Valley
  • Diablo Clinical Research - Walnut Creek
  • Focus Clinical Research - West Hills

Alabama

  • Alliance For Multispecialty Research - Daphne - Daphne
  • Eastern Shore Research Institute - Fairhope
  • Heart Center Research LLC - Huntsville
  • Mobile Heart Specialists PC - Mobile
  • Syed Research Consultants LLC - Sheffield

Florida

  • Excel Medical Clinical Trials - Boca Raton
  • Velocity Clinical Research - New Smyrna Beach - Edgewater
  • Alliance for Multispecialty Research - Fort Myers - Fort Myers
  • Indago Research and Health Center - Hialeah

Arizona

  • Synexus Clinical Research US, Inc. - Phoenix
  • Medical Advancement Centers of Arizona - Phoenix

Delaware

  • Family Practice Associates - Wilmington

Trial Details

FieldValue
Enrollment Target 12,800 participants
Start Date 2025-07-25
Est. Completion 2030-09-29
Phase Phase 3

Sponsor

Amgen

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07037433

The ClinicalTrials.gov registry entry for NCT07037433 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 12,800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 807-participant average among 1,053 other Obesity trials with a reported enrollment target (1486% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07037433 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Florida.

Frequently Asked Questions

What is clinical trial NCT07037433 about?

NCT07037433 is a clinical study titled "Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity". The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

What is the current status of trial NCT07037433?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 12,800 participants. The study started on 2025-07-25. Estimated completion is 2030-09-29.

What conditions does trial NCT07037433 study?

This clinical trial studies the following conditions: Obesity, Overweight, Atherosclerotic Cardiovascular Disease.

What interventions are being tested in trial NCT07037433?

The interventions under investigation include: Placebo (DRUG), Maridebart Cafraglutide (DRUG).

Who is sponsoring clinical trial NCT07037433?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07037433 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Overweight

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.